PubMed:20382224
Annnotations
c_corpus
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-5 | PR:Q5S006 | denotes | LRRK2 |
| T2 | 0-5 | PR:000003033 | denotes | LRRK2 |
| T3 | 0-5 | PR:Q5S007 | denotes | LRRK2 |
| T5 | 78-100 | D017173 | denotes | Caenorhabditis elegans |
| T6 | 78-100 | 6239 | denotes | Caenorhabditis elegans |
| T11 | 110-129 | D010300 | denotes | Parkinson's disease |
| T12 | 110-129 | D010300 | denotes | Parkinson's disease |
| T15 | 144-149 | PR:Q5S006 | denotes | LRRK2 |
| T16 | 144-149 | PR:000003033 | denotes | LRRK2 |
| T17 | 144-149 | PR:Q5S007 | denotes | LRRK2 |
| T18 | 196-214 | C566739 | denotes | autosomal dominant |
| T23 | 219-249 | D010300 | denotes | idiopathic Parkinson's disease |
| T24 | 219-249 | D010300 | denotes | idiopathic Parkinson's disease |
| T33 | 303-309 | D020558 | denotes | GTPase |
| T34 | 453-468 | GO:0016301 | denotes | kinase activity |
| T35 | 491-496 | PR:Q5S006 | denotes | LRRK2 |
| T36 | 491-496 | PR:000003033 | denotes | LRRK2 |
| T37 | 491-496 | PR:Q5S007 | denotes | LRRK2 |
| T38 | 507-519 | GO:0009405 | denotes | pathogenesis |
| T39 | 547-557 | SO:0000781 | denotes | transgenic |
| T40 | 584-589 | D006801 | denotes | human |
| T41 | 590-595 | PR:Q5S006 | denotes | LRRK2 |
| T42 | 590-595 | PR:000003033 | denotes | LRRK2 |
| T43 | 590-595 | PR:Q5S007 | denotes | LRRK2 |
| T44 | 596-605 | SO:0000817 | denotes | wild type |
| T45 | 679-684 | PR:Q5S006 | denotes | LRRK2 |
| T46 | 679-684 | PR:000003033 | denotes | LRRK2 |
| T47 | 679-684 | PR:Q5S007 | denotes | LRRK2 |
| T48 | 685-693 | CHEBI:36080 | denotes | proteins |
| T49 | 810-819 | MOP:0000569 | denotes | reduction |
| T54 | 823-831 | 3628 | denotes | dopamine |
| T50 | 823-831 | CHEBI:59905 | denotes | dopamine |
| T51 | 823-831 | CHEBI:18243 | denotes | dopamine |
| T52 | 823-831 | D004298 | denotes | dopamine |
| T53 | 823-831 | D004298 | denotes | dopamine |
| T55 | 927-936 | SO:0000817 | denotes | wild type |
| T59 | 937-944 | PR:000000001 | denotes | protein |
| T56 | 937-944 | GO:0003675 | denotes | protein |
| T60 | 937-944 | SO:0000104 | denotes | protein |
| T57 | 937-944 | CHEBI:36080 | denotes | protein |
| T58 | 937-944 | CHEBI:11122 | denotes | protein |
| T65 | 986-994 | 3628 | denotes | dopamine |
| T61 | 986-994 | CHEBI:59905 | denotes | dopamine |
| T62 | 986-994 | CHEBI:18243 | denotes | dopamine |
| T63 | 986-994 | D004298 | denotes | dopamine |
| T64 | 986-994 | D004298 | denotes | dopamine |
| T66 | 1007-1012 | PR:Q5S006 | denotes | LRRK2 |
| T67 | 1007-1012 | PR:000003033 | denotes | LRRK2 |
| T68 | 1007-1012 | PR:Q5S007 | denotes | LRRK2 |
| T69 | 1089-1092 | D006160 | denotes | GTP |
| T70 | 1089-1092 | CHEBI:37565 | denotes | GTP |
| T71 | 1089-1092 | D006160 | denotes | GTP |
| T72 | 1089-1092 | CHEBI:15996 | denotes | GTP |
| T73 | 1089-1100 | GO:0005525 | denotes | GTP binding |
| T74 | 1093-1100 | SO:0100018 | denotes | binding |
| T75 | 1093-1100 | SO:0001091 | denotes | binding |
| T77 | 1157-1162 | PR:Q5S006 | denotes | LRRK2 |
| T78 | 1157-1162 | PR:000003033 | denotes | LRRK2 |
| T79 | 1157-1162 | PR:Q5S007 | denotes | LRRK2 |
| T80 | 1163-1170 | SO:0000853 | denotes | homolog |
| T81 | 1172-1177 | PR:Q9TZM3 | denotes | LRK-1 |
| T82 | 1172-1177 | PR:O80939 | denotes | LRK-1 |
| T83 | 1192-1197 | PR:Q5S006 | denotes | LRRK2 |
| T84 | 1192-1197 | PR:000003033 | denotes | LRRK2 |
| T85 | 1192-1197 | PR:Q5S007 | denotes | LRRK2 |
| T86 | 1265-1275 | SO:0000781 | denotes | transgenic |
| T87 | 1276-1281 | PR:Q5S006 | denotes | LRRK2 |
| T88 | 1276-1281 | PR:000003033 | denotes | LRRK2 |
| T89 | 1276-1281 | PR:Q5S007 | denotes | LRRK2 |
| T90 | 1387-1395 | CHEBI:59905 | denotes | dopamine |
| T91 | 1387-1395 | CHEBI:18243 | denotes | dopamine |
| T92 | 1387-1395 | D004298 | denotes | dopamine |
| T93 | 1387-1395 | D004298 | denotes | dopamine |
| T94 | 1387-1395 | 3628 | denotes | dopamine |
| T95 | 1443-1452 | MOP:0000569 | denotes | reduction |
| T96 | 1456-1464 | CHEBI:59905 | denotes | dopamine |
| T97 | 1456-1464 | CHEBI:18243 | denotes | dopamine |
| T98 | 1456-1464 | D004298 | denotes | dopamine |
| T99 | 1456-1464 | D004298 | denotes | dopamine |
| T100 | 1456-1464 | 3628 | denotes | dopamine |
| T101 | 1547-1553 | D020558 | denotes | GTPase |
| T102 | 1554-1569 | GO:0016301 | denotes | kinase activity |
| T103 | 1573-1578 | PR:Q5S006 | denotes | LRRK2 |
| T104 | 1573-1578 | PR:000003033 | denotes | LRRK2 |
| T105 | 1573-1578 | PR:Q5S007 | denotes | LRRK2 |
| T106 | 1605-1617 | D007448 | denotes | invertebrate |
| T107 | 1653-1665 | GO:0009405 | denotes | pathogenesis |
| T108 | 1726-1733 | D004194 | denotes | disease |
| T109 | 1726-1733 | D004194 | denotes | disease |
PubmedHPO
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 196-214 | HP_0000006 | denotes | autosomal dominant |
| T2 | 230-239 | HP_0001300 | denotes | Parkinson |
| T3 | 718-735 | HP_0002180 | denotes | neurodegeneration |
| T4 | 1206-1223 | HP_0002180 | denotes | neurodegeneration |
| T5 | 1228-1252 | HP_0000708 | denotes | behavioral abnormalities |
| T6 | 1342-1371 | HP_0002344 | denotes | progressive neurodegeneration |
| T7 | 1354-1371 | HP_0002180 | denotes | neurodegeneration |
Allie
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| SS1_20382224_1_0 | 230-249 | expanded | denotes | Parkinson's disease |
| SS2_20382224_1_0 | 251-253 | abbr | denotes | PD |
| SS1_20382224_3_0 | 628-640 | expanded | denotes | dopaminergic |
| SS2_20382224_3_0 | 642-644 | abbr | denotes | DA |
| AE1_20382224_1_0 | SS1_20382224_1_0 | SS2_20382224_1_0 | abbreviatedTo | Parkinson's disease,PD |
| AE1_20382224_3_0 | SS1_20382224_3_0 | SS2_20382224_3_0 | abbreviatedTo | dopaminergic,DA |
UseCases_ArguminSci_Discourse
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-130 | DRI_Challenge | denotes | LRRK2-mediated neurodegeneration and dysfunction of dopaminergic neurons in a Caenorhabditis elegans model of Parkinson's disease. |
| T2 | 131-349 | DRI_Background | denotes | Mutations in LRRK2 are thus far the most frequent known cause of autosomal dominant and idiopathic Parkinson's disease (PD) with prevalent mutations being found within the GTPase (R1441C/G) and kinase (G2019S) domains. |
| T3 | 350-469 | DRI_Background | denotes | Previous in vitro studies have revealed that R1441C and G2019S mutations are associated with increased kinase activity. |
| T4 | 470-654 | DRI_Outcome | denotes | To better understand LRRK2-linked PD pathogenesis in vivo, we have generated transgenic C. elegans overexpressing human LRRK2 wild type, R1441C and G2019S in dopaminergic (DA) neurons. |
| T5 | 655-847 | DRI_Challenge | denotes | Overexpression of these LRRK2 proteins causes age-dependent DA neurodegeneration, behavioral deficits, and locomotor dysfunction that are accompanied by a reduction of dopamine levels in vivo. |
| T6 | 848-945 | DRI_Outcome | denotes | In comparison, R1441C and G2019S mutants cause more severe phenotypes than the wild type protein. |
| T7 | 946-1057 | DRI_Background | denotes | Interestingly, treatment with exogenous dopamine rescues the LRRK2-induced behavioral and locomotor phenotypes. |
| T8 | 1058-1253 | DRI_Challenge | denotes | In contrast, expression of the GTP binding defective mutant, K1347A, or knockout of the C. elegans LRRK2 homolog, LRK-1, prevents the LRRK2-induced neurodegeneration and behavioral abnormalities. |
| T9 | 1254-1472 | DRI_Outcome | denotes | Hence, our transgenic LRRK2 C. elegans models recapitulate key features of PD including progressive neurodegeneration, impairment of dopamine-dependent behavior and locomotor function, and reduction in dopamine levels. |
| T10 | 1473-1598 | DRI_Outcome | denotes | Furthermore, our findings provide strong support for the critical role of GTPase/kinase activity in LRRK2-linked pathologies. |
| T11 | 1599-1734 | DRI_Challenge | denotes | These invertebrate models will be useful for studying pathogenesis of PD and for development of potential therapeutics for the disease. |
PubMed_ArguminSci
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 131-349 | DRI_Background | denotes | Mutations in LRRK2 are thus far the most frequent known cause of autosomal dominant and idiopathic Parkinson's disease (PD) with prevalent mutations being found within the GTPase (R1441C/G) and kinase (G2019S) domains. |
| T2 | 350-469 | DRI_Background | denotes | Previous in vitro studies have revealed that R1441C and G2019S mutations are associated with increased kinase activity. |
| T3 | 470-654 | DRI_Outcome | denotes | To better understand LRRK2-linked PD pathogenesis in vivo, we have generated transgenic C. elegans overexpressing human LRRK2 wild type, R1441C and G2019S in dopaminergic (DA) neurons. |
| T4 | 655-847 | DRI_Challenge | denotes | Overexpression of these LRRK2 proteins causes age-dependent DA neurodegeneration, behavioral deficits, and locomotor dysfunction that are accompanied by a reduction of dopamine levels in vivo. |
| T5 | 848-945 | DRI_Outcome | denotes | In comparison, R1441C and G2019S mutants cause more severe phenotypes than the wild type protein. |
| T6 | 946-1057 | DRI_Background | denotes | Interestingly, treatment with exogenous dopamine rescues the LRRK2-induced behavioral and locomotor phenotypes. |
| T7 | 1058-1253 | DRI_Challenge | denotes | In contrast, expression of the GTP binding defective mutant, K1347A, or knockout of the C. elegans LRRK2 homolog, LRK-1, prevents the LRRK2-induced neurodegeneration and behavioral abnormalities. |
| T8 | 1254-1472 | DRI_Outcome | denotes | Hence, our transgenic LRRK2 C. elegans models recapitulate key features of PD including progressive neurodegeneration, impairment of dopamine-dependent behavior and locomotor function, and reduction in dopamine levels. |
| T9 | 1473-1598 | DRI_Outcome | denotes | Furthermore, our findings provide strong support for the critical role of GTPase/kinase activity in LRRK2-linked pathologies. |
| T10 | 1599-1734 | DRI_Challenge | denotes | These invertebrate models will be useful for studying pathogenesis of PD and for development of potential therapeutics for the disease. |
DisGeNET5_variant_disease
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 20382224-3#137#143#geners33939927 | 607-613 | geners33939927 | denotes | R1441C |
| 20382224-3#148#154#geners34637584 | 618-624 | geners34637584 | denotes | G2019S |
| 20382224-3#34#36#diseaseC0030567 | 504-506 | diseaseC0030567 | denotes | PD |
| 137#143#geners3393992734#36#diseaseC0030567 | 20382224-3#137#143#geners33939927 | 20382224-3#34#36#diseaseC0030567 | associated_with | R1441C,PD |
| 148#154#geners3463758434#36#diseaseC0030567 | 20382224-3#148#154#geners34637584 | 20382224-3#34#36#diseaseC0030567 | associated_with | G2019S,PD |
DisGeNET5_gene_disease
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| 20382224-0#0#5#gene120892 | 0-5 | gene120892 | denotes | LRRK2 |
| 20382224-0#37#48#diseaseC3887505 | 37-48 | diseaseC3887505 | denotes | dysfunction |
| 20382224-0#110#129#diseaseC0030567 | 110-129 | diseaseC0030567 | denotes | Parkinson's disease |
| 20382224-7#31#34#gene92170 | 1089-1092 | gene92170 | denotes | GTP |
| 20382224-7#99#104#gene120892 | 1157-1162 | gene120892 | denotes | LRRK2 |
| 20382224-7#134#139#gene120892 | 1192-1197 | gene120892 | denotes | LRRK2 |
| 20382224-7#170#194#diseaseC0233514 | 1228-1252 | diseaseC0233514 | denotes | behavioral abnormalities |
| 0#5#gene12089237#48#diseaseC3887505 | 20382224-0#0#5#gene120892 | 20382224-0#37#48#diseaseC3887505 | associated_with | LRRK2,dysfunction |
| 0#5#gene120892110#129#diseaseC0030567 | 20382224-0#0#5#gene120892 | 20382224-0#110#129#diseaseC0030567 | associated_with | LRRK2,Parkinson's disease |
| 31#34#gene92170170#194#diseaseC0233514 | 20382224-7#31#34#gene92170 | 20382224-7#170#194#diseaseC0233514 | associated_with | GTP,behavioral abnormalities |
| 99#104#gene120892170#194#diseaseC0233514 | 20382224-7#99#104#gene120892 | 20382224-7#170#194#diseaseC0233514 | associated_with | LRRK2,behavioral abnormalities |
| 134#139#gene120892170#194#diseaseC0233514 | 20382224-7#134#139#gene120892 | 20382224-7#170#194#diseaseC0233514 | associated_with | LRRK2,behavioral abnormalities |